- Home
- KOD vs PRCT Comparison
KOD vs PRCT Comparison
Compare KOD & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOD | PRCT |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KOD | PRCT |
|---|---|---|
| Price | $23.70 | $25.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $28.29 | ★ $35.44 |
| AVG Volume (30 Days) | 510.9K | ★ 2.1M |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.60 | 1.71 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | N/A | $32.85 |
| Revenue Next Year | N/A | $24.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $1.92 | $19.35 |
| 52 Week High | $31.18 | $64.89 |
Technical Indicators
Market Signals| Indicator | KOD | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 43.43 | 46.86 |
| Support Level | $21.19 | $19.35 |
| Resistance Level | $26.21 | $29.24 |
| Average True Range (ATR) | 1.71 | 2.16 |
| MACD | -0.27 | 0.21 |
| Stochastic Oscillator | 14.96 | 72.52 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.